CASE REPORT article
Front. Oncol.
Sec. Cardio-Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1538786
This article is part of the Research TopicCase Reports in Cardio-Oncology: 2024View all 14 articles
Case Report: Primary Cardiac Diffuse Large B-cell Lymphoma with Sick Sinus Syndrome and Literature Review on Disease Management and Therapeutic Strategies
Provisionally accepted
- 1The Second People's Hospital of Quzhou, Quzhou, Zhejiang Province, China
- 2Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Primary cardiac diffuse large B-cell lymphoma (DLBCL) is a rare but clinically challenging extranodal lymphoma. Diagnosis and management are often complicated due to its nonspecific symptoms and rarity.Case Report: We reported a case of a 73-year-old male who initially presented with chest pain, high fever, dizziness, and amaurosis. Preliminary diagnostic assessments suggested sick sinus syndrome, necessitating the implantation of a dual-chamber pacemaker, and revealed a large mass in the interatrial septum. An endomyocardial biopsy confirmed the diagnosis of primary cardiac DLBCL. Initial treatment with R-miniCHOP chemotherapy yielded a partial response. However, due to treatment-related complications (grade 4 neutropenia and pneumonia), a change in the therapeutic regimen to OR-GemOx chemotherapy was made, leading to complete remission. A year later, the patient experienced a relapse, requiring a salvage treatment of the Pola-BR chemotherapy regimen, which again resulted in complete remission. Additionally, this review examines an in-depth literature review on the management and therapeutic strategies for this entity, focusing on the treatment recommendations for relapse/refractory disease.Prompt diagnosis and effective management are crucial in treating primary cardiac DLBCL. While the emergence of new drugs has improved the prognosis by offering higher efficacy and fewer side effects, clinicians should be vigilant about potential cardiotoxicities.
Keywords: primary cardiac lymphoma, Diffuse large B-cell lymphoma, Extranodal lymphoma, Sick Sinus Syndrome, Orelbrutinib, Polatuzumab vedotin
Received: 03 Dec 2024; Accepted: 17 Jun 2025.
Copyright: © 2025 Qiu, Zhang, Zhou, Qian, Liang, Qiu and Yuan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xianggui Yuan, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.